title: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
abstract: OBJECTIVE
  The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic pancreatic cancer. These encouraging data led Cancer and Leukemia Group B (CALGB) to conduct a double-blind, placebo-controlled, randomized phase III trial of gemcitabine/bevacizumab versus gemcitabine/placebo in advanced pancreatic cancer patients.
  
  
  METHODS
  Eligible patients had no prior therapy for advanced disease, Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2, no tumor invasion of adjacent organs, and no increased bleeding risk. The primary end point was overall survival. Patients were stratified by performance status, extent of disease, and prior radiotherapy. Patients received gemcitabine at 1,000 mg/m(2) over 30 minutes on days 1, 8, and 15 every 28 days and bevacizumab at 10 mg/kg or placebo on days 1 and 15 every 28 days.
  
  
  RESULTS
  Between June 2004 and April 2006, 602 patients were enrolled onto the study and 535 were treated. Median overall survival was 5.8 months for gemcitabine/bevacizumab and 5.9 months for gemcitabine/placebo (P = .95). Median progression-free survival was 3.8 and 2.9 months, respectively (P = .07). Overall response rates were 13% and 10%, respectively. Patients with a performance status of 0, 1, and 2 survived a median of 7.9, 4.8, and 2.4 months, respectively. The only statistically significant differences in grades 3 and 4 toxicity occurred for hypertension (10% v 3%; P < .001) and proteinuria (5% v 1%; P = .002); venous thrombosis grade > or = 3 was equivalent in both arms (14% and 15%, respectively).
  
  
  CONCLUSIONS
  The addition of bevacizumab to gemcitabine does not improve survival in advanced pancreatic cancer patients.
authors.affiliation: University of Chicago Cancer Research Center, Chicago, IL 60637-1470, USA. hkindler@medicine.bsd.uchicago.edu
authors.forename: Hedy Lee
authors.initials: HL
authors.lastname: Kindler
authors.forename: Donna
authors.initials: D
authors.lastname: Niedzwiecki
authors.forename: Donna
authors.initials: D
authors.lastname: Hollis
authors.forename: Susan
authors.initials: S
authors.lastname: Sutherland
authors.forename: Deborah
authors.initials: D
authors.lastname: Schrag
authors.forename: Herbert
authors.initials: H
authors.lastname: Hurwitz
authors.forename: Federico
authors.initials: F
authors.lastname: Innocenti
authors.forename: Mary Frances
authors.initials: MF
authors.lastname: Mulcahy
authors.forename: Eileen
authors.initials: E
authors.lastname: O'Reilly
authors.forename: Timothy F
authors.initials: TF
authors.lastname: Wozniak
authors.forename: Joel
authors.initials: J
authors.lastname: Picus
authors.forename: Pankaj
authors.initials: P
authors.lastname: Bhargava
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Mayer
authors.forename: Richard L
authors.initials: RL
authors.lastname: Schilsky
authors.forename: Richard M
authors.initials: RM
authors.lastname: Goldberg
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D010919:Placebos; D000093542:Gemcitabine
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D010919:Placebos; D003841:Deoxycytidine; D000068258:Bevacizumab; D000093542:Gemcitabine